← CalciMedica, Inc. (CALC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CalciMedica, Inc. (CALC)
Pharmaceutical Preparations · market cap $12M · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
8
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
CalciMedica (CALC) is a micro-cap pharmaceutical preparations company with a market cap of about $44M (~34.1M shares, ~$1.3/share). Its pipeline in our database is made up of Phase 2 programs: Auxora in acute kidney injury (the lead asset), pneumonia and acute pancreatitis, plus CM4620 formulations in acute pancreatitis. The company closed an offering on 2026-09-30 and reports $18.6M cash and about 12.1 months of runway, with an estimated Phase 2 CM4620 event on 2027-01-15.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-01-15 (est.)Phase 2 · CM4620imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Auxora | Phase 2 | Acute Kidney Injury |
| Auxora (Part 1) | Phase 2 | Pneumonia |
| CM4620-IE | Phase 2 | Acute Pancreatitis |
| CM-4620 Injectable Emulsion or CM-4620-IE | Phase 2 | Acute Pancreatitis |
| CM4620 Injectable Emulsion (Low Dose) | Phase 2 | Acute Pancreatitis |
| CM4620 | Phase 2 | Acute Pancreatitis |
| CM4620 Injectable Emulsion (High Dose) | Phase 2 | Acute Pancreatitis |
| Auxora (Part 2) | Phase 2 | Pneumonia |
Price & technical context
3-month
-62.2%
6-month
-59.0%
12-month
-91.5%
52-wk range
$1.02–$33.70
vs 50-day MA
-20.7%
vs 200-day MA
-63.0%
Realized vol
188.5%
Max drawdown
-97.0%
Daily closes through 2026-11-05. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CALC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.